Scolaris Content Display Scolaris Content Display

Table 1. Comparison of interventions

Study

Drug A

Drug B

Control

Dose

Frequency

Type of inhaler

Notes

Avital 1992

Salbutamol

Ipratropium

Placebo

Salbutamol: 2.5 mg         Ipratropium: 0.25 mg

Single dose

Cross‐over trial. Methacholine challenge doubling concentrations of inhaled methacholine 5 minutes apart with FEV1

Dodd 2005

Salbutamol

Placebo

Salbutamol: 600 mcg         Ipratropium: 0.25 mg

Single dose

Cross‐over trial. 

Duncan 1982

Salbutamol

Saline

Salbutamol: 0.5 mg

prior to physiotherapy (3 days)

Cross‐over trial. 

Eggleston 1991

Albuterol

Placebo

Albuterol: 90 mcg

4x daily (4 weeks)

MDI

Cross‐over trial. Participants subdivided into responders or non‐responders by methacholine challenge

Hordvik 1996

Albuterol

Placebo

5mg

3x prior to CPT (1 day)

Cross‐over trial. 

Hordvik 1999

Albuterol

Salmeterol

Placebo

Albuterol: 180 mcg
Salmeterol: 42 mcg

Albuterol: 4x prior to CPT (1 day)
Salmeterol: 2x prior to 1st and 4th CPT (1 day)                                     
Placebo:  4x prior to CPT (1 day) 

MDI

3‐way cross‐over trial 

Hordvik 2002

Albuterol & placebo

Salmeterol & placebo

Albuterol: 2.5 mg              Salmeterol: 100 mcg

both given 2x daily (Short‐term arm 4 weeks; long‐term arm 26 weeks).

Cross‐over trial. Abuterol nebulised and placebo discus; Salmeterol discus and placebo nebulised.

Konig 1998

Albuterol

Placebo

Albuterol: 180 mcg

2x daily (6 months)

MDI

Cross‐over trial.

Pitcher 1982

Salbutamol

Ipratropium

Saline

Salbutamol: 5 ‐ 10 mg         Ipratropium: 250 ‐ 500 mcg

Single dose (2 ‐ 6 months)

Cross‐over trial.

Salvatore 2002

Salmeterol

Placebo

Salmeterol: 84 mcg

1x daily (45 mins before bed), repeat 48 hours later

Cross‐over trial. Day 1: albuterol challenge (200 mcg via MDI) to determine responders

Sanchez 1992

Albuterol

Ipratropium

Placebo

Albuterol: 5 mg                         
Ipratropium: 2.5 mg

Single dose of each (3 days)

Cross‐over trial.

Sanchez 1993

Salbutamol

Ipratropium

Salbutamol: 200 ‐ 400 mcg           Ipratropium: 80 mcg

Single dose of each sequence, dose of each drug separated by 45 mins (2 days).

MDI & aerochamber

Cross‐over trial. Sequence A: salbutamol 200 mcg, salbutamol 400 mcg and ipratropium 80 mcg; or Sequence B: ipratropium 80 mcg, salbutamol 200 mcg, salbutamol 400 mcg

Serisier 2007

Salbutamol

Placebo

Salbutamol: 600 mcg 

Single dose prior to cycle ergometry.

MDI with spacer

Cross‐over trial. Histamine challenge test was performed to assess bronchial hyper‐reactivity but no information given.

Sheehan 2003

Albuterol

Placebo

Albuterol: 180 mcg

Albuterol: 2 minute intervals until heat rate increased by 10% (maximum of 8 puffs);             
Placebo: 2 puffs at 2 minute intervals (maximum 6 puffs).

MDI with spacer (Aerochamber MV)

Parallel trial.

Turchetta 1996

Salbutamol

Salmeterol

Salbutamol: 2 puffs     Salmeterol: 2 puffs

Salbutamol: 3x daily (30 days)     
Salmeterol: 2x daily (30 days)

Cross‐over trial. No washout period.

Turchetta 1998

Salmeterol

Placebo

2 puffs

2x daily (1 month)

MDI with spacer

Parallel trial.

Wiebicke 1990

Ipratropium bromide solution

0.9 % hypertonic saline solution

Ipratropium bromide: 2 ml  Hypertonic saline: 2 ml

Single dose of each (over 2 weeks)

Cross‐over trial. Ipratropium bromide solution (Atrovent® = 250 ?g in 1 ml hypertonic saline solution).

Ziebach 2001

Salbutamol

Ipratropium

Placebo

Salbutamol: 5 mg                    Ipratropium: 0.25 mg  

Single dose of each (4 days)

Cross‐over trial. Randomised to nebulised placebo, salbutamol, ipratropium or combination.

Figures and Tables -
Table 1. Comparison of interventions